Table 5.
Select studies related to first-line therapy in NSCLC patients with EGFR mutations
| Author/trial (year) | Number | RR
|
PFS (months)
|
OS (months)
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TKI | Chemotherapy | TKI | Chemotherapy | TKI | Chemotherapy | |||||
| IPASS (2008, 2011)51,52 | 261 | 71.2% | 47.3% | 9.5 | 6.3 | 21.6 | 21.9 | |||
| P<0.001 | HR 0.48 (0.34–0.64) P<0.001 |
HR 1.00 (0.76–1.33) P=0.990 |
||||||||
| WJTOG 3405 (2010, 2012)78,79 | 177 | 62.1% | 32.2% | 9.2 | 6.3 | 35.5 | 38.8 | |||
| P<0.001 | HR 0.489 (0.336–0.710) P<0.001 |
HR 1.185 P=0.443 |
||||||||
| OPTIMAL (2011)104 | 154 | 83.0% | 36.0% | 13.7 | 4.6 | 22.6 | 28.8 | |||
| P<0.001 | HR 0.16 (0.10–0.26) P<0.001 |
HR 1.065 P=0.685 |
||||||||
| First-SIGNAL (2012) | 42 | 84.6% | 37.5% | 8.0 | 6.3 | 27.2 | 25.6 | |||
| P=0.002 | HR 0.544 (0.269–1.100) P=0.086 |
HR 1.043 (0.498–2.182) P=0.984 |
||||||||
| EURTAC (2012)105 | 173 | 58.0% | 15.0% | 9.7 | 5.2 | 19.3 | 19.5 | |||
| P<0.001 | HR 0.37 (0.25–0.54) | HR 1.04 P=0.87 |
||||||||
| EJ002 (2013)106 | 228 | 73.7% | 30.7% | 10.8 | 5.4 | 27.7 | 26.6 | |||
| P<0.001 | HR 0.322 (0.236–0.438) P<0.001 |
HR 0.887 (0.634–1.241) P=0.483 |
||||||||
| X-Lung 3 (2013)108 | 345 | 56.0% | 23.0% | 11.1 | 6.9 | |||||
| P=0.001 | HR 0.58 (0.43–0.78) P=0.001 |
HR 1.12 (0.73–1.73) P=0.60 |
||||||||
| UX-Lung 6 (2014)109 | 364 | 66.9% | 23.0% | 11.0 | 5.6 | 22.1 | 22.2 | |||
| P<0.0001 | HR 0.28 (0.20–0.39) P<0.0001 |
HR 0.95 (0.68–1.33) P=0.76 |
||||||||
Note: The number ranges given after HR values are 95% confidence interval.
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; IPASS, IRESSA Pan-Asia Study; WJTOG, West Japan Thoracic Oncology Group; First-SIGNAL, First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung; EURTAC, European Tarceva versus Chemotherapy; RR, response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; TKI, tyrosine kinase inhibitors.